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Objective: To examine the efﬁcacy and safety of Huo-Luo-Xiao-Ling (HLXL)-Dan, a Traditional Chinese
Medicine (TCM), in patients with knee osteoarthritis (OA).
Design: A multi-site, randomized, double-blind, placebo-controlled phase II dose-escalation clinical trial
was conducted. Eligible patients who fulﬁlled American College of Rheumatology criteria were ran-
domized to receive either HLXL or placebo. Clinical assessments included measurement of knee pain and
function with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), patient
global assessment (PGA), and knee pain scores every 2 weeks. A Data and Safety Monitoring Board
(DSMB) was established to review the data for ensuring the quality of the trial.
Results: In the ﬁrst stage, 28 participants were randomized to receive either low-dose HLXL-Dan
(2400 mg/day) or placebo for 6 weeks. The results showed no statistical difference between the two
groups. The study was then re-designed following the recommendation of DSMB. Ninety-two patients
were enrolled in the second stage and were randomized to receive either high-dose HLXL-Dan (4000 mg/
day for week 1e2, and 5600 mg/day for week 3e8) or placebo for 8 weeks. All outcome assessments
showed signiﬁcant improvements for both groups after 8 weeks but no signiﬁcant between-group dif-
ferences. The change (mean ± SD) of WOMAC pain and WOMAC function scores of HLXL and placebo
group after 8 weeks were 1.2 ± 1.7 vs 1.4 ± 1.5, and 1.1 ± 1.6 vs 1.3 ± 1.5 respectively. No serious
adverse events were reported.
Conclusion: Although safe to use, an 8-week treatment of HLXL-Dan was not superior to placebo for
reduction in pain or functional improvement in patients with knee OA.
Clinical trial registration number: Clinicaltrials.gov (NCT00755326).
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.o: L. Lao, School of Chinese
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Osteoarthritis (OA) is the most common form of arthritis1. OA of
knee is a major cause of morbidity, physical limitation, and
increased health care utilization2, and it is a leading cause of
disability in the older adults3. It is now recognized that inﬂam-
mation in joints affected by OA contributes to not only the devel-
opment of symptoms, including pain and stiffness, but also thetd. All rights reserved.
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tion4,5. Conventional analgesic medications such as acetamino-
phen, and nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
commonly used for the treatment of OA6,7. However, their use is
limited by concerns regarding potentially serious adverse effects.
Nonpharmacologic treatments including patient education, weight
loss, exercise, and physical therapy have showed substantial beneﬁt
and are recommended to the patients with OA8, but these treat-
ments are still underutilized9. Given the limitations of the con-
ventional treatments, complementary and alternative medicine
(CAM) are commonly used by patients with OA. It was found that
nearly one-third of older adults reported using at least one form of
CAM modality for treating OA10. However, despite high usage of
CAM by patients with OA, the scientiﬁc evidence for the efﬁcacy of
these modalities in OA is far from conclusive11. Huo-Luo-Xiao-Ling
(HLXL)-Dan (pills) is a widely used traditional Chinese herbal
medicine for the treatment of arthritis12,13. In animal studies, HLXL-
Dan has demonstrated signiﬁcant anti-inﬂammatory effects14e16.
Previous clinical trials and case-series studies suggested that HLXL
is effective for various types of arthritis, including gout, rheumatoid
arthritis, and OA17e20. To our knowledge, however, there has been
no prior randomized, double-blind, placebo-controlled trial to
examine the efﬁcacy of HLXL-Dan for knee OA.
The aims of this phase II dose-escalation, double-blind, ran-
domized clinical trial were to determine whether HLXL improves
pain and/or function in patients with OA of the knee who continue
to have symptoms despite receiving standard analgesic and/or
NSAID treatment, and to identify an optimal dosage of HLXL as well
as its safety and tolerability.Methods
Patient recruitment
The trial was conducted from April 2007 to May 2011 at the
University of Maryland Center for Integrative Medicine, Baltimore,
Maryland and from April 2010 to May 2011 at the Chinese Uni-
versity of Hong Kong, Hong Kong SAR, China. The trial was
approved by the Institutional Review Board (IRB) at both the Uni-
versity of Maryland School of Medicine and Chinese University of
Hong Kong. We obtained permission for an Investigational New
Drug (IND) from the Food and Drug Administration (FDA), regis-
tration number, 70,327. A Data and Safety Monitoring Board
(DSMB) was established, which met annually to review the data for
ensuring the safety of the trial. The trial was performed in
compliance with the Helsinki Declaration and ICH-GCP. We fol-
lowed the CONSORT recommendations in designing and reporting
of controlled trials21. The trial was registered at Clinicaltrials.gov
(NCT00755326).
Patients meeting the following inclusion criteria were recruited
to the trial: age 40 years or older, diagnosis of OA of the knee of at
least 6 months duration fulﬁlling American College of Rheuma-
tology criteria, pain in at least one knee of at least moderate
severity (Likert scale [none, mild, moderate, severe, extreme] or
visual analog scale (VAS) pain score of at least 40 [0e100]) on most
(at least 15) days of the previous 1 month, taking analgesic or
NSAIDs for control of pain, documented radiographic changes
indicating OA of the knee (KellgreneLawrence grade greater than
or equal to 2 at the time of screening), stable on arthritis medica-
tions for previous 1 month, willingness and ability, with help of a
caregiver if necessary, to comply with treatment and follow-up
procedures, not pregnant or lactating, use of effective contracep-
tion if woman of childbearing potential, and signed consent state-
ment. Exclusion criteria were medical condition that may precludesafe participation in protocol or prevents completion of the study
(see Appendix for detailed exclusion criteria).
In the USA site, advertisements in local newspapers and local
radios were used for patients’ recruitment; in the Hong Kong site,
patients in the Rheumatoid clinic were approached for recruitment.
After a brief telephone screening, patients were scheduled for an
on-site screening examination that included a protocol-driven ex-
amination of the knees by a trained physician or nurse practitioner.
If eligible, the patient was randomly assigned to either the HLXL
treatment group or a placebo control group by a computer-
generated process using randomly selected block sizes. We
assured the allocation concealment by using a web-based
randomization program, which would not reveal the randomiza-
tion result for each participant until the recruiting coordinator
entered the participant ID, following completion of the screening
and qualiﬁcation process. The participants were randomly assigned
to HLXL or placebo in a 2:1 ratio at the low dose with a block size
ranged 3 to 6. After the DSMB recommended two weeks at the
middle dose for safety reasons followed by the high dose, the
randomization ratio was set to 1:1 with a block size ranged 2 to 4.
All participants and research teammembers were blinded to group
assignment until the end of each dose stage. Only the statistician
and data analyst were privy to trial results until after presentation
to the DSMB.
Study intervention
HLXL is an ancient prescription that has been used for over 100
years in the treatment of arthritis in China. The original HLXL had
only 4 herbs, and there have been many varieties of formula in
Traditional Chinese Medicine (TCM) history. The HLXL examined in
this study contains 11 individual herbs modiﬁed from the original
classic formula, and is a popular treatment for inﬂammatory dis-
eases in China22e24. The composition of the composite extract was
previously published (14) and listed here: (1) Ruxiang (Boswellia
carterii Birdw., 17.8%) (gum resin), (2) Qianghuo (Notopterygium
incisum Ting ex H.T. Chang., 9.5%) (root & rhizome), (3) Danggui
(Angelica sinensis (Oliv.) Diels., 11.6%) (root), (4) Baishao (Paeonia
lactiﬂora Pall., 10.0%) (root, rootlets, bark), (5) Gancao (Glycyrrhiza
uralensis Fisch., 9.7%) (root), (6) Yanhusuo (Corydalis yanhusuoW.T.
Wang., 1.8%) (root), (7) Danshen (Salvia miltiorrhiza Bge., 1.8%)
(root), (8) Chuanxiong (Ligusticum chuanxiong S.H. Qiu., 9.2%) (root),
(9) Qinjiao (Gentiana macrophylla, Pall, 10%) (root), (10) Guizhi
(Cinnamomum cassia Presl, 4.1%) (root), (11) Duhuo (Angelica
pubescens Maxim., 14.4%) (root).
The herbs were extracted using 70% aqueous acetone. For
quality control purposes, high performance liquid chromatography
(HPLC) ﬁngerprint was generated (Fig. 1). A single batch of study
extracts was used for the entire trial and periodic stability tests
were performed every 90 days to ensure the stability of the
investigational herbal extracts.
The human dosage in this study was determined by converting
from the animal experiment14 based on the following equation on
the selection of a safe starting dose for (non-repeated dosing) initial
human trials, as per FDA guidance (134): HED (g/kg) ¼ animal
dosage (g/kg)  (Wt of animal ÷ Wt of human)1-b. Whereas
HED ¼ human equivalent dose, effective dosage in
animal ¼ 0.575 g/kg HLXL, rat weight ¼ 0.25 kg, human
weight ¼ 60 kg, 1-b ¼ 0.33, 134 then, human daily
dosage ¼ HED  Humanweight (60 kg) ¼ about 5 g. HLXL capsules
contain 0.370 g/capsule, therefore, daily use in the highest dosage
condition will be 14 capsules.
The original dosage escalation design involved three dosage
levels: low (6 capsules/day), medium (10 capsules/day), and high
(14 capsules/day). Each capsule contained 400 mg HLXL. The
Fig. 1. HPLC chromatogram of HLXLa, b. a (1) ¼ Boswellia carterii, (2) ¼ Notopterygium
incisum, (3) ¼ Angelica sinensis, (4) ¼ Paeonia lactiﬂora, (5) ¼ Glycyrrhiza uralensis
(6) ¼ Corydalis yanhusuo, (7) ¼ Salvia miltiorrhiza (8) ¼ Ligusticum chuanxiong,
(9) ¼ Gentiana macrophylla, (10) ¼ Cinnamomum cassia, (11) ¼ Angelica pubescens. b(1)-
1, (1)-2, (1)-3 ¼ Boswellia carterii characteristic peaks 1, 2 and 3 respectively; (2)-1, (2)-
2, (2)-3, (2)-4 ¼ Notopterygium incisum characteristic peaks 1, 2, 3 and 4 respectively;
etc.
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sizes were originally estimated at n ¼ 60 per dose level in a treat-
ment to control ratio of 2:1 (40 HLXL, 20 Placebo), and 180 in total
(120 HLXL, 60 Placebo).
Because the lowest dose was found to have no effect and no
adverse effects after the completion of the ﬁrst 28 subjects, and low
recruitment rate was observed, the trial was re-designed. The
DSMB recommended merging the medium and high dose stages
into one medium to high dose trial and extending the treatment
period by 2 weeks. Therefore, in this re-designed medium to high
dose trial, the subjects in the HLXL group received themedium dose
of HLXL (10 capsules/day or 4000 mg/day) in the ﬁrst 2 weeks to
evaluate safety. If no adverse effects were observed, the dose was
increased to 14 capsules per day (5600 mg/day) for the subsequent
6 weeks. Subjects in the placebo group received an equal number of
placebo capsule. Our previous phase I trial in seven patients found
that the dose of HLXL, 5180 mg daily (7 capsules, 2 times daily),
showed no serious adverse effects (data not shown). In addition,
the sample size was modiﬁed to n ¼ 100 in a 1:1 ratio of HLXL to
placebo, 50 subjects in each group. Assumptions for sample size
estimation were based on results of the prior pilot study for
WOMAC pain and function scales, change from baseline, SD
(pain) ¼ 1.75, SD (function) ¼ 1.76, on a scale of 0e10. With
power ¼ 0.8, alpha ¼ 0.05% and 4% dropout (actual), we calculated
that with 50 patients per group we could detect differences in
pain ¼ 0.98 and function ¼ 0.99. Reductions in pain and function
scores were greater than these detectable differences; clearly we
had adequate power.
The placebo was made from a list of FDA approved ingredients/
excipient that matched the color and taste of the real HLXL herbal
extract, instead of just white powder used in other placebo trials.
Same size and color of capsules were used for the placebo and
herbal extract. The equivalent number of capsules used in the
treatment group at each dose level were administered to patients
assigned to the control group.
Outcome measures
Outcome assessments were conducted at baseline, 2, 4, and 6
weeks after randomization in the low dose stage (low dose trial);after re-designing the study (mediumehigh dose trial), assess-
ments were performed at 2, 4, 6 and 8 weeks after randomization.
The primary outcomes were changes from baseline in the VAS
version of Western Ontario and McMaster Universities Osteoar-
thritis Index (WOMAC) pain and function scores. The primary
endpoint was considered the end of the herbal intervention (week
6 for the stage 1 low dose trial and week 8 for the stage 2 medi-
umehigh dose trial). The secondary outcomes were change in pa-
tient global assessment (PGA) of knee OA severity, change in
WOMAC stiffness subscale score, adverse drug reactions, and
adherence as measured by pill count and diary.
Statistical analysis
Analyses were carried out under the intention-to-treat princi-
ple; that is, all available data for all randomized participants were
included in all analyses, with no data imputation. Initial analyses
tabulated demographic and baseline characteristics of the study
participants by randomization group and dosage level, where the
medium and highest dose results were combined and termed high
dose.
For outcome analyses, paired t-tests were used to assess changes
from baseline by treatment group in primary and (where appro-
priate) secondary outcomes; independent two-sample Student's t-
tests were used to compare treatment groups on change from
baseline in continuous outcome measures. Finally, mixed-effect
model methods (based on the Generalized Estimating Equation
(GEE) principle) were used to compare treatment groups on out-
comes with adjustment for covariates identiﬁed as potential con-
founders or variables on which the groups differed at baseline; no
variables were found to be signiﬁcantly associated with outcome or
to change the observed effect size when included. Interactions of
treatment group with site (Baltimore or Hong Kong) were also
investigated and found to be non-signiﬁcant. Thus, GEE adjusted
results were not presented. We did not power the trial to carry out
subgroup analyses as part of the primary outcome analyses.
Results
After the completion of 28 subjects in the low dose trial, where
no differences were observed between treatment groups and no
adverse effects were observed, the sample size and treatment
dosage were adjusted following the recommendation of the DSMB
(Supplementary Table). In the re-designed mediumehigh dose
trial, we enrolled 92 patients, 53 in the US and 39 in Hong Kong.
(Fig. 2). In this report, we present the results from the medium-
ehigh dose trial only. At baseline, the mean age was 60 years, 65
(71%) were women and 64 (70%) were of Asian ethnicity with
symptomatic OA of the knee (Table I). The mean WOMAC pain and
function scores were 4.4 (SD ¼ 1.6) and 4.5 (SD ¼ 1.7), respectively.
The dropout rates were not signiﬁcantly different between the
HLXL group (4.3%) and placebo group (6.7%). No serious AEs were
identiﬁed.
Although both HLXL and placebo groups showed signiﬁcant
improvement in WOMAC normalized score (primary endpoint),
PGA and knee pain scores at week 8, no statistically signiﬁcant
between-group differences were found in any of the efﬁcacy end-
points (Table II). The results were the same when the US site and
Hong Kong site were analyzed separately. There were no signiﬁcant
interactions of clinical site and treatment group identiﬁed.
With respect to adverse reactions, our previous Phase I pilot
study had identiﬁed skin rash, GI events and possibly small in-
creases in transaminases as potential AE's for the high dose HLXL
(unpublished data). In this study, no additional toxicities of the
HLXL compound were identiﬁed. Speciﬁcally, there were no ALT
Fig. 2. Patient ﬂowchart (High-dose trial).
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elevations above the upper limit of normal. Nausea and mild
bloating were reported by a few subjects, probably related to the
investigational drug, but did not lead to dropout of subjects. Two
individuals developed rash. One subject discontinued HLXL treat-
ment after developing an allergic reaction; another developed
transient urticaria but completed the study. One individual devel-
oped worsening of hypertension and hypokalemia. In a comparison
with the placebo control, the frequency and intensity of reported
adverse events in the HLXL group were not signiﬁcantly different
from those in the control group (Table III).
Discussion
In this randomized, double-blinded, placebo-controlled phase II
dose-escalation clinical trial evaluating the effect and safety of
HLXL-Dan, we found that, although safe to use, an 8-week treat-
ment of this classic Chinese herbal formula in the proposed capsule
format was not superior to placebo control for pain management or
functional improvement in patients with knee OA. Despite thewide
use of HLXL with different ways of disposure in treating arthritis inthe Chinese population, based on the results of this study, we
cannot recommend HLXL as an adjunctive therapy for treating knee
OA.
There were several reasons for examining HLXL. First, this for-
mula is widely used to treat joint pain, known as “Bi” syndrome in
TCM12,13,22. Second, prior to our clinical trial, we tested the efﬁcacy
and mechanisms of action of this formula in an inﬂammatory pain
animal model. In those studies, HLXL-Dan signiﬁcantly suppressed
complete Freund's adjuvant (CFA)-induced inﬂammatory pain14,
and it reduced inﬂammation by suppressing pro-inﬂammatory
cytokines such TNF-alpha and IL-1beta in local tissue15. Therefore,
HLXL could be a potential effective treatment for knee OA and is
warranted to be examined by a rigorously designed clinical trial to
examine its efﬁcacy.
In contrast to most clinical trials of Chinese herbal medicine that
were often criticized for lack of adequate methodological design
and implementation25, this clinical trial was rigorously designed
with a carefully calculated sample size, adequate randomization
and allocation concealment, a valid placebo control, standard
outcome measures, and adequate follow-up time. It was monitored
by an external DSMB. A botanical core consisting of a team of
Table I
Demographics and baseline health characteristics
Baseline characteristic Total group n ¼ 92 HLXL (n ¼ 47) Placebo (n ¼ 45)
n (%) or mean ± SD
Age (years) 60 ± 9 60 ± 8 60 ± 9
Gender
Male 27 (29) (31) (28)
Female 65 (71) (69) (72)
Race/ethnicity
White, non-Hispanic 16 (17) (18) (17)
Black, non-Hispanic 10 (11) (9) (13)
Hispanic 2 (2) (0) (4)
Asian or Paciﬁc Islander 64 (70) (73) (66)
WOMAC e Osteoarthritis Index*
Pain normalized score 4.3 ± 1.5 4.1 ± 1.4 4.4 ± 1.6
Function normalized score 4.2 ± 1.6 3.9 ± 1.4 4.5 ± 1.7
Overall normalized score 12.9 ± 4.5 12.2 ± 4.0 13.7 ± 4.9
PGAy 2.2 ± 0.8 2.2 ± 0.8 2.3 ± 0.7
Knee painz
Right knee 53.6 ± 21.6 54.2 ± 15.1 53.0 ± 26.2
Left knee 49.6 ± 24.2 48.2 ± 23.4 50.9 ± 25.1
Average of both knees 51.6 ± 17.1 51.2 ± 15.9 51.9 ± 18.2
* Pain normalized score and function normalized score are on a scale of 0e10, with 10 indicating extreme pain/difﬁculty related to knee arthritis and 0 indicating no
pain/difﬁcultly related to knee arthritis. Overall normalized score is on a scale of 0e30, and is the sum of the pain, stiffness and function normalized scores (each on a scale
of 0e10).
y PGA is on a scale of 1e5, with 5 indicating excellent and 1 indicating poor (in response to the question “Considering all the ways that your OA of the knee affects you,
how are you feeling today?”
z Knee pain is on a scale of 0e100, with 100 indicating worst pain ever and 0 indicating no pain experienced, on average, over the last 48 h.
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the herbal product. A single batch of high-quality extract was
employed throughout the trial, and the product was monitored and
found to be stable throughout the trial. We are conﬁdent that our
data are reliable and accurate.
The study was planned to recruit 60 participants in the stage 1
low dose trial, and 60 participants each in the medium dose and
high dose trials. However, since we did not ﬁnd any signiﬁcantTable II
Treatment effect as measured at baseline, week 2 and week 8 (high dose only, combined
Characteristic n Baseline Week 2 Change
WOMACz
Pain normalized score
HLXL 47 4.4 ± 1.6 4.1 ± 1.8 0.4 ± 1.1
Placebo 45 4.1 ± 1.4 3.4 ± 1.5 0.7 ± 1.3
Function norm'd score
HLXL 46 4.5 ± 1.7 4.1 ± 2.0 0.4 ± 1.1
Placebo 44 3.9 ± 1.4 3.4 ± 1.7 0.5 ± 1.3
Overall norm'd score
HLXL 46 13.7 ± 4.9 12.6 ± 5.5 1.2 ± 3.3
Placebo 44 12.2 ± 4.0 10.6 ± 4.5 1.6 ± 3.6
PGAx
HLXL 47 2.3 ± 0.7 2.4 ± 0.8 0.1 ± 0.8
Placebo 45 2.2 ± 0.8 2.6 ± 0.8 0.4 ± 0.9
Knee pain¶
Right knee
HLXL 47 53.0 ± 26.1 49.8 ± 25.1 3.2 ± 23.4
Placebo 45 54.2 ± 15.1 44.7 ± 19.6 9.6 ± 15.5
Left knee
HLXL 47 50.9 ± 25.1 46.8 ± 29.8 4.0 ± 23.7
Placebo 45 48.2 ± 23.4 41.6 ± 21.7 6.7 ± 20.6
Average of both knees
HLXL 47 51.9 ± 18.3 48.3 ± 24.4 3.6 ± 18.5
Placebo 45 51.2 ± 15.9 43.1 ± 18.2 8.1 ± 16.0
* P values from paired t-test, comparing change from baseline to week 2 or baseline t
y P values from independent two-sample Student's t-test, comparing change in HLXL
z Pain normalized score and function normalized score are on a scale of 0e10, with 10
difﬁcultly related to knee arthritis. Overall normalized score is on a scale of 0e30, and is th
x PGA is on a scale of 1e5, with 5 indicating excellent and 1 indicating poor (in respons
are you feeling today?”).
¶ Knee pain is on a scale of 0e100, with 100 indicating worst pain ever and 0 indicatidifference after completion of the ﬁrst 28 participants during the
stage 1 low dose trial, we followed the recommendation of the
DSMB to re-design the study. The timely adjustment of the protocol
ensured that research resources and participants' efforts would not
be wasted.
The present phase II clinical trial is designed based on our
previous animal studies14,15, inwhich an optimal dose of HLXL with
maximal efﬁcacy and minimal adverse events was determined. TheBaltimore and Hong Kong sites)
P value* P valuey Week 8 Change P value* P valuey
0.17 0.47
0.03 3.3 ± 1.9 1.2 ± 1.7 <0.01
<0.01 2.7 ± 1.7 1.4 ± 1.5 <0.01
0.72 0.51
<0.01 3.6 ± 2.0 1.1 ± 1.6 <0.01
0.01 2.7 ± 1.4 1.3 ± 1.5 <0.01
0.54 0.45
0.02 10.6 ± 5.8 3.6 ± 4.6 <0.01
<0.01 8.2 ± 4.4 4.3 ± 4.2 <0.01
0.14 0.82
0.36 2.7 ± 1.0 0.4 ± 0.9 <0.01
<0.01 2.7 ± 1.0 0.5 ± 0.9 <0.01
0.13 0.39
0.36 42.0 ± 25.4 11.5 ± 24.4 <0.01
<0.01 39.5 ± 21.7 15.4 ± 16.1 <0.01
0.57 0.35
0.25 43.3 ± 29.1 7.2 ± 23.5 0.04
0.04 37.8 ± 24.7 11.5 ± 18.4 <0.01
0.22 0.28
0.19 42.6 ± 24.6 9.3 ± 19.0 <0.01
<0.01 38.7 ± 21.8 13.4 ± 15.1 <0.01
o week 8, as appropriate.
group to change in placebo group.
indicating extreme pain/difﬁculty related to knee arthritis and 0 indicating no pain/
e sum of the pain, stiffness and function normalized scores (each on a scale of 0e10).
e to the question “Considering all the ways that your OA of the knee affects you, how
ng no pain experienced, on average, over the last 48 h.
Table III
Summary of adverse events by treatment groups
Total HLXL Placebo P value*
Total number AE reported 64 35 29
Severity Mild 60 33 27 0.85
Moderate 4 2 2
Severe 0 0 0
Likelihood caused by drug Probably 10 5 5
Possibly 3 2 1 0.93
Probably not 14 7 7
Deﬁnitely not 37 21 16
* P values were based on chi-square test of differences between HLXL and placebo group.
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adverse events. Therefore, it was converted into human equivalent
dose and examined in this study. Our results indicated that the
optimal dose of HLXL (5600 mg/day) is also safe and well-tolerated
in human, without causing any signiﬁcant adverse events and
serious adverse event.
Despite its wide usage and its anti-inﬂammatory properties,
which were conﬁrmed by our pre-clinical studies, HLXL-Dan in the
speciﬁc form of standardization and formulation showed no ben-
eﬁts beyond placebo in any of the dosages tested in this phase II
clinical trial. Thus, based on the results of this trial, we cannot
recommend its use in the treatment of knee OA. However, several
factors might explain the inconsistencies between these ﬁndings
and those of our basic science research: First, this formula might
not be suitable for knee OA, which is not characterized by a sys-
temic inﬂammatory component. HLXL-Dan might be more suitable
for systemic inﬂammatory arthritis such as rheumatoid arthritis.
Second, the formula might not be potent enough to provide addi-
tional symptom relief for patients already on background analge-
sics and/or NSAIDs. The classic formula was used in ancient times
when no other analgesics were available. Third, TCM, as is well
known, is an individualized modality in which a single disease may
be treated with various formulae chosen to ﬁt patients’ symptoms
and constitutions. Standard placebo-controlled trial methodsmight
not be the most effective way to examine the efﬁcacy of TCM
formulae or assess the effectiveness of TCM practice. A carefully
designed trial that employs individualized treatment and medica-
tions might be a better way to evaluate the usefulness of Chinese
herbal formulas. Fourth, in the present study, the herbs were
extracted using 70% aqueous acetone, which has been found to be
an efﬁcient extraction method for Chinese herbal medicine14,26. In
tradition, however, the herbs were usually by water extraction.
Acetone is more efﬁcient than water in extracting ingredients from
herbal medicine, but it extracts both non-polar and polar-
components. Therefore, it is possible that some water insoluble
ingredients were also extracted by acetone, which may affect the
absorption in human, leading to differences in treatment efﬁcacy.
An important lesson that we learnt from this study is that, prior
to a large scale phase III trial, a smaller scale phase II trial is
necessary, because this approach allows us to evaluate the efﬁcacy
and safety of an herbal formula in a relatively small scaled, cost-
effective trial. It has been reported that a number of large scale
studies on herbal medicine failed to conﬁrm their beneﬁts seen in
earlier preliminary studies27; for example, St John's wort for
attention deﬁcit hyperactivity disorder (ADHD)28, saw palmetto for
benign prostatic hyperplasia29, and ginkgo biloba for early cogni-
tive decline30. Although HLXL has demonstrated signiﬁcant anti-
inﬂammatory effects in previous animal studies14e16, the results
of the present phase II trial suggested that HLXL in 5600 mg/day is
not warranted to be further examined in a large scale phase III trial.
In conclusion, our study found that an 8-week treatment of
HLXL-Dan capsules was safe and well-tolerated, but not superior toplacebo control for pain management or functional improvement
in patients with knee OA. Future studies employing individualized
treatment and medications might be more appropriate to assess
the efﬁcacy of Chinese medicine treatment.
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Appendix. Exclusion criteria
Uncontrolled angina and/or congestive heart failure, severe
chronic obstructive pulmonary disease, active treatment for cancer,
major psychiatric disease, other severe systemic disease, or signif-
icant abnormalities on screening physical examination and labo-
ratory tests that reveal clinically important abnormalities of
hematological, cardiac, pulmonary, metabolic, renal, hepatic,
gastrointestinal or other systems, intra-articular (IA) corticosteroid
injection of either knee within a 3 month interval immediately
prior to baseline screening, IA hyaluronates in either knee within
L. Lao et al. / Osteoarthritis and Cartilage 23 (2015) 2102e21082108the past 6 months, Tidal lavage or arthroscopy of either kneewithin
the past 12months, current use of topical capsaicin cream on either
knee, blood pressure over 180 mm Hg systolic or 100 mm Hg dia-
stolic (at either the second or third of triplicate measurements), use
of any constituent herb in HLXL within the past 3 months, current
use of Chinese herbs for arthritis, use of oral prednisone in the past
30 days, history or clinical indications of bleeding diathesis,
including current use of anti-coagulants, use of any investigational
drug within the past 30 days, inﬂammatory arthritis (e.g., rheu-
matoid or psoriatic arthritis), currently participating in another
intervention research study, unwilling to be randomized, plan to
move residence away from the immediate area within the next 2
months, drug or alcohol abuse sufﬁcient to hinder compliance with
treatment or follow-up procedures.
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Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.joca.2015.06.007.
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